As Chair of Foley Hoag's Licensing & Strategic Alliances Practice Group, partner Hemmie Chang regularly handles high profile intellectual property matters. Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the life sciences, energy and cleantech and technology sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals - all of which involve a broad range of intellectual property assets, from brand names to copyright, patents to trade secrets. Hemmie is also very active within the firm’s Business Department and Life Science and Technology practice groups.
Most recently, Hemmie negotiated collaborations for Zosano's transdermal delivery technology with Novo Nordisk and Living Proof's Strateris™ platform with Valeant Pharmaceuticals, represented Metamark Genetics in its $365 million collaboration with Janssen Pharmaceuticals, and advised on early stage research agreements with AstraZeneca, GSK, Medtronic, Merck and Sanofi. Hemmie is often sought out for comment as an expert on licensing and strategic alliance topics. She was recently invited to write "Partnering Prenuptials: Translating Priorities into Deal Terms" for The Burrill Report (June 2013), and has been quoted in the World Intellectual Property Review and The Pink Sheet, "In 2012, Buyer’s Market Made Alliances Rarer," January 7, 2013.